Unknown PHASE3 INTERVENTIONAL 2-arm NCT02029820

RenalGuard System for Prevention of Contrast Induced Nephropathy (REPRECIN)

RenalGuard System for Prevention of Contrast Induced Nephropathy - A Randomized Trial

Sponsor: Hospital Sao Lucas da PUCRS

Conditions Radiographic Contrast Agent Nephropathy

Interventions RenalGuard

Updated 4 times since 2017 Last updated: Jan 6, 2014 Started: Aug 31, 2012 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02029820, this PHASE3 trial focuses on Radiographic Contrast Agent Nephropathy and remains ongoing. Sponsored by Hospital Sao Lucas da PUCRS, it has been updated 4 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Sao Lucas da PUCRS

Data source: Hospital Sao Lucas da PUCRS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Porto Alegre, Brazil